Abstract
Fluid bolus therapy (FBT) is one of prime management in early goal-directed therapy (EGDT) to achieve adequate cardiac output. The Fluid Expansion as Supportive Therapy (FEAST) trial, a randomized-clinical trial that was used as an evidence to support fluid resuscitation recommendation in Surviving Sepsis Campaign (SSC) 2020, must be discontinued because of increasing mortality in the group that received higher volume of FBT. We present a case of a 9-year-old girl, 15 kg, came to emergency ward with refractory septic shock and became fluid overload after the second FBT. This proceeding aimed to deliver evidence-based case practice if the comparison between liberal versus restrictive FBT in children with septic shock.
Irene Yuniar
